CV Therapeutics Inc (CVTX) after Tuesday's closing bell reported a third-quarter net loss of $62.7 million, or $1.23 a share, compared with $55.9 million, or $1.26 a share, during the same period a year ago. The Palo Alto, Calif.-based biopharmaceutical company posted operating revenue of $12.2 million vs. $4.14 million. Analysts polled by Thomson First Call had forecast a third-quarter loss of $1.44 a share on revenue of $12 million. Additionally, the company said it recorded $8.2 million of net product revenue for sales of its chronic angina treatment Ranexa during the quarter, compared with $1.2 million during the previous quarter ended June 30.